Back to search results
NCT07213648

Modification of Threat Interpretation Bias to Reduce Anxiety in Neurodegenerative Movement Disorders (Aim 3)

Active, Not Recruiting
NAAges 21+InterventionalSupportive care
University of Virginia
~136 participants
Updated 2026-07-20 on ClinicalTrials.gov
What's tested:MindTrails-MovementWaitlist Control

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Quality of Life in Neurological Disorders (NeuroQoL) Anxiety short form
Measured over From baseline to end of week 6

Conditions

Huntington Disease
Parkinson Disease

Explore related trials

Huntington's DiseaseParkinson Disease

NCT07213648

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Univeristy of Virginia School of Nursing

    Charlottesville, Virginiano site contact published

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Clinical diagnosis of Huntington's disease or Parkinson's disease (genetic diagnosis of HD also acceptable)
With anxiety symptoms (NeuroQoL Anxiety ≥12)

Exclusion

Cognitive decline precluding ability to consent or complete the intervention (MoCA 5 min/telephone ≤11)
Unable to read and understand English
Does not have regular access to an internet-connected device, capable of downloading and installing the mobile application (i.e., tablet or iPhone running iOS 10 or later or an Android phone running Android 5.0 or later)
Not located in the USA
\<21 years old
Active suicidality based on the answer "yes" to questions 4, 5, or 6b of the Columbia-Suicide Severity Rating Scale (Screen version)

What this trial measures

  • Quality of Life in Neurological Disorders (NeuroQoL) Anxiety short formFrom baseline to end of week 6

    Patient-reported anxiety symptoms will be measured using the Quality of Life in Neurological Disorders Anxiety short form (NeuroQoL-Anxiety) total raw scores. This measure includes 8 items ranked 1-5, where the total score is the sum of item scores (range 8-40), and higher scores indicate worse anxiety symptoms.